Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02483247 · ClinicalTrials.gov registry record · Phase 1
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 165
- Enrollment target
NCT02483247 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 165 participants.
The verdict
NCT02483247, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 165 participants
- Enrollment target
Study Summary
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the study is to determine the safety, tolerability, and RP2D of BBI503 in combination with each of the selected anti-cancer agents.
Interventions
- DRUG Pembrolizumab
- DRUG Capecitabine
- DRUG Doxorubicin
- DRUG Nivolumab
- DRUG BBI503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02483247
The ClinicalTrials.gov registry entry for NCT02483247 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02483247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02483247 about?
NCT02483247 is a clinical study titled "A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer". This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the study is to determine the safety, tolerability, and RP2D of BBI503 in combination with each of the selected anti-c...
What is the current status of trial NCT02483247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2015-09. Estimated completion is 2019-05.
What interventions are being tested in trial NCT02483247?
The interventions under investigation include: Pembrolizumab (DRUG), Capecitabine (DRUG), Doxorubicin (DRUG), Nivolumab (DRUG), BBI503 (DRUG).
Who is sponsoring clinical trial NCT02483247?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.